SCHEMBL6624850

SCHEMBL6624850

O=C(Cc1cscc1NS(=O)(=O)c1ccc(-c2ccc(Cl)cc2)cc1)N1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.45
MAPK1 P28482 2/20 0.43
EGFR P00533 1/20 0.43
TYMS P04818 1/20 0.43
LTA4H P09960 1/20 0.43
VDR P11473 1/20 0.43
SRC P12931 1/20 0.43
CTSK P43235 1/20 0.43
SLC2A2 P11168 1/20 0.43
PHGDH O43175 1/20 0.43
LMNA P02545 4/20 0.42
MAPT P10636 3/20 0.42
TP53 P04637 2/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 2/20 0.42
KMT2A Q03164 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MITF O75030 1/20 0.41
PAX8 Q06710 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6613171 0.91 MAPT (0.53) MAPK1SLC2A2LMNAMAPTHTT
SCHEMBL6626941 0.91 ALDH1A1 (0.42) HSD11B1MAPK1LMNAMAPTHTT
SCHEMBL6623723 0.91 KMT2A (0.48) HSD11B1MAPK1LMNAALDH1A1KMT2A
SCHEMBL6623941 0.89 ALDH1A1 (0.41) HSD11B1MAPK1LMNAMAPTHTT
SCHEMBL6624482 0.88 NPC1 (0.42) HSD11B1MAPK1LMNAHTTALDH1A1
SCHEMBL6627742 0.87 ALDH1A1 (0.55) MAPK1LMNAMAPTTP53HTT
SCHEMBL6625889 0.86 L3MBTL1 (0.46) LMNATP53HTTSMN1; SMN2ALDH1A1
SCHEMBL7080427 0.85 KMT2A (0.47) MAPK1LMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL6698640 0.85 KMT2A (0.45) CTSKLMNAMAPTTP53HTT
SCHEMBL6624174 0.85 GHSR (0.41) MAPK1LMNAMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885MAPK1 978/4885EGFR 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.